Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784)
08/2003
08/14/2003WO2002058626A3 Methods and compositions for the identification and treatment of neurodegenerative disorders
08/14/2003WO2002055560A3 Monoclonal antibodies specific for the e2 glycoprotein of hepatitis c virus and their use in the diagnosis, treatment, and prevention of hepatitis c
08/14/2003WO2002051438A3 Use of repulsive guidance molecule (rgm) and its modulators
08/14/2003WO2002047718A3 Methods and compositions for vaccination comprising nucleic acid ad/or polypeptide sequences of $i(chlamydia)
08/14/2003WO2002039116A3 Retrovirus isolated from humans
08/14/2003WO2002029055A3 Carbohydrate-associated proteins
08/14/2003WO2002024887A3 Ligand/receptor specificity exchangers that redirect antibodies to receptors on a pathogen
08/14/2003WO2002024735A3 Peptide inhibitors of hiv entry
08/14/2003WO2002024145A9 Antiviral substances from plant cuticular and epicuticular material
08/14/2003WO2002020051A3 Equine infectious anemia challenge model for testing vaccines, diagnostics and treatments
08/14/2003WO2001092527A3 Regulators of apoptosis
08/14/2003WO2001090148A3 Neurotransmitter transporters
08/14/2003US20030153757 Synthesis and purification of valacyclovir
08/14/2003US20030153747 Depletion of 7-aminodesacetoxy-cephalosporonic acid in a mixture with 7-amino-3-vinyl-cephalosporonic acid
08/14/2003US20030153744 Such as 4-amino-7-(2'deoxy,-beta-l-erythro-pento-furanosyl) pyrrolo(2,3-D)pyrimidine for treatment of hepatitis B virus infection with reduced side effects
08/14/2003US20030153733 Antibiotic resistant drug screening; vaccines
08/14/2003US20030153727 Controlling protein levels in eucaryotic organisms
08/14/2003US20030153622 Ophthalmic solution and contact lens solution
08/14/2003US20030153621 Administering mixtures of 13-hydroxyoctadeca-9Z,11E-dienoic acid (13-HODE) and carriers comprising glycerides or fatty esters as controllers of endothelial growth factors
08/14/2003US20030153618 Treatment and prevention of herpes simplex infections
08/14/2003US20030153605 Enzyme inhibitors of nitric oxide synthase
08/14/2003US20030153604 Anticoagulants
08/14/2003US20030153569 Novel pyrazole and pyrazoline substituted compounds
08/14/2003US20030153568 Serine/threonine and tyrosine kinases inhibitors
08/14/2003US20030153561 Pyrroloquinolones as antiviral agents
08/14/2003US20030153559 Treatment of an oxygen and/or energy deficit; a poly(adenosine diphosphate ribose)-polymerase inhibitor; treating autoimmune, neurodegenerative and diseases caused by a toxic effect; viricides
08/14/2003US20030153558 Immunomodulators and/or inhibiting cytokine release
08/14/2003US20030153549 Clavulinic acid derivatives; antibiotics
08/14/2003US20030153544 Fatty acid derivatives
08/14/2003US20030153534 Phosphonate nucleotide compound
08/14/2003US20030153525 Identifies differential expression of 1465, 1587, 2146, 2207, 32838, 336 OR 52908 genes in tissues relating to pain sensation relative to their expression in normal or non-painful disease states
08/14/2003US20030153523 Screening library of test compounds, each of which is attached to a solid support, with a dye-labeled RNA molecule to form a dye-labeled target RNA:support-attached test compound complex
08/14/2003US20030153518 Activation and inhibition of the immune system
08/14/2003US20030153516 Methods and materials for treating and preventing inflammation of mucosal tissue
08/14/2003US20030153512 An etherification product of curcumin and saccharide glucose, use as antitumor agents treating cancer, antiinflammatory agents and viricides for treating a retrovirus infections
08/14/2003US20030153510 Novel compounds inhibiting factor xa activity
08/14/2003US20030153507 HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
08/14/2003US20030153506 Anticoagulant therapy; multicompartment kits, synergistic effect using the mixtures
08/14/2003US20030153504 Antiinflammatory agents selects from a group of tetrapeptides, hexapeptides, octapeptides, oligopeptides, polypeptides
08/14/2003US20030153502 A water-soluble polypeptide having hydrophobic side chains, for use as bactericides treating infections, detoxification of endotoxin, cell antiproliferative agents, antagonist of tumor necrosis factor
08/14/2003US20030153500 Use of EGF to inhibit pathogenic infections
08/14/2003US20030153191 Antibiotics; storage stability
08/14/2003US20030153073 Expansion of T cells in vitro and expanded T cell populations
08/14/2003US20030153066 Isolating nucleic acid putatively encoding the viral gene from the viral genome; programming a cell-free translation system with such nucleic acid, determine if capsid assembly has occurred which indicates that viral gene is required
08/14/2003US20030152986 Method for sorting antifungal molecules acting on the glucanosyltransferase activity
08/14/2003US20030152651 Herbal composition for angina pectoris, method to prepare same and uses thereof
08/14/2003US20030152594 Immunology response intensifiers; administering a bacterial lysate
08/14/2003US20030152589 Infecting with bacteriophage; inducting immunology response; forming antibodies
08/14/2003US20030152587 Immunomoderators; high molecular weight polysaccharides
08/14/2003US20030152583 Dna which codes complex
08/14/2003US20030152582 CTL epitopes from EBV
08/14/2003US20030152569 Method for removing and reducing Hepatitis C virus
08/14/2003US20030152552 Synergistic mixture; viricides, antiproliferative agents, antiinflammatory agents; side effect reduction
08/14/2003US20030152550 Dendritic cells and the uses thereof in screening cellular targets and potential drugs
08/14/2003US20030152530 Aqueous solution of calcium ions and stabilising agent, aqueous solution of phosphate ions and stabilising agent wherein calcium and phosphate ions are present in amounts sufficient to form on mixing a supersaturated solution thereof
08/14/2003US20030152520 5-Substituted-2-arylpyridines
08/14/2003DE10201747C1 Glas-Keramik-Komposit, Verfahren zu seiner Herstellung und Verwendungen Glass-ceramic composite, method for its preparation and uses
08/14/2003CA2485064A1 Albumin-fused kunitz domain peptides
08/14/2003CA2483630A1 Compositions and methods for modulation of effects on phagocyte and lymphoid cell populations
08/14/2003CA2482559A1 Processes for preparing crystalline and amorphous mupirocin calcium
08/14/2003CA2475637A1 Quinolinone derivatives for treating cell proliferation related disorders
08/14/2003CA2475539A1 Hiv inhibiting proteins
08/14/2003CA2475446A1 Viral variants with altered susceptibility to nucleoside analogs and uses thereof
08/14/2003CA2475382A1 Albumin-fused anti-angiogenesis peptides
08/14/2003CA2475329A1 Truncated aggrecanase molecules
08/14/2003CA2475326A1 A continuous cell line for the production of vaccines
08/14/2003CA2475247A1 Anti-pathogen treatments
08/14/2003CA2475101A1 Recombinant bovine immunodeficiency virus based gene transfer system
08/14/2003CA2475036A1 Antimicrobial thiadiazinone derivatives useful in treatment of bacterial infections
08/14/2003CA2474974A1 Cytoprotective benzofuran derivatives
08/14/2003CA2474921A1 Pharmaceutical tablet
08/14/2003CA2474917A1 Granzyme b inhibitors
08/14/2003CA2474748A1 Inhibitors of alpha l beta 2 integrin mediated cell adhesion
08/14/2003CA2474709A1 Immunostimulatory, covalently lipidated oligonucleotides
08/14/2003CA2474508A1 Ansamycins having improved pharmacological and biological properties
08/14/2003CA2474398A1 New immunoeffector compounds
08/14/2003CA2474186A1 Compositions and methods for restoring immune responsiveness in patients with immunological defects
08/14/2003CA2474145A1 Bacteriophage lysin
08/14/2003CA2474016A1 A combination for treating cold and cough
08/14/2003CA2473724A1 Purine and isosteric antibacterial compounds
08/14/2003CA2472265A1 Immunogenic formulations of variable peptidic epitopes and process for preparation thereof
08/14/2003CA2472249A1 Pharmaceutical compositions for hepatitis c viral protease inhibitors
08/14/2003CA2471207A1 Method of inhibiting pathogenicity of infectious agents
08/14/2003CA2469748A1 Methods and formulations for eradicating or alleviating staphylococcal nasal colonization using lysostaphin
08/14/2003CA2467555A1 Preparation of pharmaceutical salts of 4 ( (z) - (4-bromophenyl) (ethoxyimino) methyl)-1'-( (2,4-dimethyl-1-oxido-3-pyridinyl) carbonyl) -4'-me thyl-1,4' bipiperidine as ccr5-antagonists for the treatment of aids and related hiv infections
08/14/2003CA2466251A1 Therapeutic use of aziridino compounds
08/14/2003CA2464527A1 Multivalent streptococcal vaccine compositions and methods for use
08/14/2003CA2451650A1 Ligands to enhance cellular uptake of biomolecules
08/13/2003EP1335023A2 Methods and reagents for vaccination which generate a CD8 T cell immune response
08/13/2003EP1335019A1 T cell line and use thereof
08/13/2003EP1334971A1 Benzimidazole compounds, process for producing the same and use thereof
08/13/2003EP1334727A2 Method for obtaining antigenic structures enhancing specific cross reactivity
08/13/2003EP1334717A2 Pharmaceutical Compositions For Oral And Topical Administration
08/13/2003EP1334201A2 Dna expression vectors
08/13/2003EP1334197A1 Yeast derived vaccine against ipnv
08/13/2003EP1334192A2 Cystoskeleton-associated proteins
08/13/2003EP1334131A1 Monoclonal antibodies to the map protein and method of use in treating or preventing infections
08/13/2003EP1334124A2 Diastereomeric peptides and pharmaceutical compositions comprising them
08/13/2003EP1334118A2 Methods and reagents for regulation of cellular responses in biological systems
08/13/2003EP1334117A1 Antibacterial agents comprising conjugates of glycopeptides and peptidic membrane-associating elements
1 ... 1158 1159 1160 1161 1162 1163 1164 1165 1166 1167 1168 1169 1170 1171 1172 1173 1174 1175 1176 1177 1178 ... 1798